TY - JOUR
T1 - The herbal medicine Sho-saiko-to inhibits growth and metastasis of malignant melanoma primarily developed in ret-transgenic mice
AU - Kato, M.
AU - Liu, W.
AU - Yi, H.
AU - Asai, N.
AU - Hayakawa, A.
AU - Kozaki, K. I.
AU - Takahashi, M.
AU - Nakashima, I.
N1 - Funding Information:
We thank K. Uchiyama, Y. Umeda, and K. Ban for technical assistance. This study was supported in part by Grants-in-Aid for Scientific Research on Priority Areas, for COE Research, and for Encouragement of Young Scientists from the Ministry of Education Science, Sports and Culture of Japan, fund for Comprehensive Research on Aging and Health and by grants from Daiko Foundation, Aichi Cancer Research Foundation, the Research Foundation for Oriental Medicine, the Japan Institute of Traditional-Medicine, the Tokai Science Academy, and the International Dermatology Exchange Fund of Japan.
PY - 1998
Y1 - 1998
N2 - Sho-saiko-to is the most popular herbal medicine in Japan. We investigated the anti-tumor and anti-metastatic effects of Sho-saiko-to and its chemically defined ingredients on the primary skin melanoma that developed in a metallothionein-I (MT)/ret transgenic mouse line and on a melanoma cell line (Mel-ret), which was derived from a primary tumor developed in a MT/ret transgenic mouse. In vitro, Sho-Saiko-to suppressed the growth of Mel-ret cells more strongly than any single ingredient of Sho- saiko-to, although baicalin as one of several ingredients tested also suppressed it significantly. In vivo, Sho-saiko-to (i) significantly (p < 0.02) prolonged the onset of tumor development (1.5 mo), (ii) definitely retarded the transition to malignancy, (iii) significantly decreased the incidence of distant metastasis to brain (p < 0.002), kidney (p < 0.05), and liver (p < 0.05) at the malignant stage, and (iv) significantly (p < 0.02) prolonged life span (2.6 mo). Moreover, Sho-saiko-to and baicalin down- regulated the matrix metalloproteinase-2 and -9 expression levels, and upregulated their inhibitor expression level in both the primary tumors and Mel-ret cells. In conclusion, Sho-saiko-to displayed anti-tumor and antimetastatic effects on melanoma with regulation of the balance of matrix metalloproteinase and tissue inhibitor of the matrix metalloproteinase levels.
AB - Sho-saiko-to is the most popular herbal medicine in Japan. We investigated the anti-tumor and anti-metastatic effects of Sho-saiko-to and its chemically defined ingredients on the primary skin melanoma that developed in a metallothionein-I (MT)/ret transgenic mouse line and on a melanoma cell line (Mel-ret), which was derived from a primary tumor developed in a MT/ret transgenic mouse. In vitro, Sho-Saiko-to suppressed the growth of Mel-ret cells more strongly than any single ingredient of Sho- saiko-to, although baicalin as one of several ingredients tested also suppressed it significantly. In vivo, Sho-saiko-to (i) significantly (p < 0.02) prolonged the onset of tumor development (1.5 mo), (ii) definitely retarded the transition to malignancy, (iii) significantly decreased the incidence of distant metastasis to brain (p < 0.002), kidney (p < 0.05), and liver (p < 0.05) at the malignant stage, and (iv) significantly (p < 0.02) prolonged life span (2.6 mo). Moreover, Sho-saiko-to and baicalin down- regulated the matrix metalloproteinase-2 and -9 expression levels, and upregulated their inhibitor expression level in both the primary tumors and Mel-ret cells. In conclusion, Sho-saiko-to displayed anti-tumor and antimetastatic effects on melanoma with regulation of the balance of matrix metalloproteinase and tissue inhibitor of the matrix metalloproteinase levels.
UR - http://www.scopus.com/inward/record.url?scp=0031664362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031664362&partnerID=8YFLogxK
U2 - 10.1046/j.1523-1747.1998.00341.x
DO - 10.1046/j.1523-1747.1998.00341.x
M3 - Article
C2 - 9764846
AN - SCOPUS:0031664362
SN - 0022-202X
VL - 111
SP - 640
EP - 644
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 4
ER -